In this regard, anti-LAG-3 therapy is in phase I trials and based on encouraging preclinical results in MHC II expressing tumors, such as Hodgkin’s Lymphoma; anti-LAG3 therapy in combination with anti-PD1 is also under clinical investigation. Here, LAG3 is linked to Hodgkins lymphoma.